Search clinical trials for: Interferon injections and ribavirin

Total 8943 results

Bayer

Completed

China Betaferon Adherence, Coping and Nurse Support Study

Multiple Sclerosis, Chronic Progressive

China
Bayer

Completed

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (SEPLUS)

Multiple Sclerosis

France
Rutgers, The State University of New Jersey
Bayer

Completed

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

Multiple Sclerosis

United States
Biogen

Completed

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

Healthy

United States
Merck KGaA, Darmstadt, Germany

Completed

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone (RETURN)

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone (REMAIN)

Multiple Sclerosis, Relapsing-Remitting
Bayer

Completed

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis (BREAK)

Multiple Sclerosis

Poland
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
Bayer

Completed

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Multiple Sclerosis

Canada, United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Essential Thrombocytopenia

China
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
Sun Yat-sen University
First People's Hospital of Foshan; Eighth Affiliated Hospital, Sun Yat-sen...

Recruiting

To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. (IFNA2/ISGs)

Hepatitis B

China
Bayer

Completed

Depression and Fatigue in MS Patients Treated With Betaferon. (FADO)

Multiple Sclerosis

Poland
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Multiple Sclerosis

Germany
Bayer

Completed

BENEFIT Extension Study

Multiple Sclerosis

Switzerland, Poland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Slovenia, Israel, Belgium, Denmark, Netherlands, Canada, Norway, Finland
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

HIV Infections

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Relapsing Remitting Multiple Sclerosis
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Bayer

Completed

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (INFLUENCE)

Multiple Sclerosis

Poland
Bayer

Completed

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Multiple Sclerosis

China
Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark
Bayer

Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Unspecified Childhood Solid Tumor, Protocol Specific | Neoplasm of Uncertain Malignant Potential

United States
Bayer

Completed

Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy

Heart Diseases | Cardiomyopathies

Italy, Spain, Germany, Poland, United Kingdom, Sweden, France
Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
University of Chicago

Unknown

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Immune System Diseases | Multiple Sclerosis

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Melanoma (Skin)

United States
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV

HIV Infections

Spain
Merck Sharp & Dohme LLC

Completed

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
SPP Pharmaclon Ltd.

Completed

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

COVID-19 Respiratory Infection | Acute Respiratory Disease

Russian Federation
Bayer

Completed

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

Multiple Sclerosis

United States
Biogen

Completed

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (SFERA)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Clinical Isolated Syndrome (CIS)

Czech Republic, Switzerland
King Abdulaziz Medical City

Completed

Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

Chronic Hepatitis C Virus

Saudi Arabia
EMD Serono
Pfizer

Completed

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (RNF)

Multiple Sclerosis

United States
Biogen

Completed

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Multiple Sclerosis | Pregnancy | Prenatal Exposure Delayed Effects

United States
Bayer

Completed

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Bayer

Completed

BEYOND Pilot Study

Multiple Sclerosis | Relapsing-Remitting

United States
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Completed

Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)

Hepatitis C

Egypt
Beijing Ditan Hospital

Unknown

A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis

Chronic Hepatitis b

China
Tongji Hospital

Unknown

Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

COVID-19 | Recombinant Human Interferon α1β
University Hospital Tuebingen

Completed

NAM-Trial: Multiferon in Malignant Melanoma

Locoregional Metastases in Malignant Melanoma Stages IIIB/C

Germany
Novartis Pharmaceuticals

Completed

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (NICOLI)

Chronic Myeloid Leukemia

Germany
University of Arizona

Completed

Cognitive Effects of Interferon in Patients With Melanoma

Melanoma

United States
European Organisation for Research and Treatment...

Unknown

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Switzerland, Netherlands, Poland, Finland, Belgium, United Kingdom, Austria, Germany, Italy, Israel, Slovakia, Spain, Serbia, Portugal, Russian Federation, Bulgaria, Croatia, Turkey, Estonia, Sweden
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

France, Germany, Italy, Japan, United States, Australia, Puerto Rico, Spain, New Zealand
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
Kexing Biopharm Co., Ltd.
The Third Hospital of Changsha; Guoxin Pharmaceutical Technology (Beijing)... and other collaborators

Completed

A Phase I Study in Healthy Participants

Healthy Participants

China
Seoul National University Hospital
Roche Pharma AG; SciClone Pharmaceuticals

Completed

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
Lee's Pharmaceutical Limited

Not yet recruiting

Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer

Herpes Zoster

3

Subscribe